TheraRadar
← Back
Data updated: Mar 29, 2026

PF PRISM CV

OncologyInfectious DiseaseDermatology
Big Pharma

PF PRISM CV is a major pharmaceutical company focused on Oncology, Infectious Disease, Dermatology. Key products include XELJANZ.

1999
Since
11
Drugs
-
Trials
23
Approved (2yr)

Key Drugs

XELJANZ
tofacitinib citrate
JAK1 5 indications · 2012
INLYTA
axitinib
VEGFR-1 3 indications · 2012
XALKORI
crizotinib
Oncology
ALK 3 indications · 2011
BOSULIF
bosutinib monohydrate
BCR-ABL kinase 1 indications · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

VFEND 2026-02-19
Labeling
VFEND 2026-02-19
Labeling
VFEND 2026-02-19
Labeling
VFEND 2026-01-28
Labeling
VFEND 2026-01-28
Labeling
VFEND 2026-01-28
Labeling
XELJANZ 2025-10-16
Efficacy
XELJANZ 2025-10-16
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 50%
3 drugs
Infectious Disease 33%
2 drugs
Dermatology 17%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Oncology, Dermatology
COSETTE other
Dermatology, Infectious Disease, Oncology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology